Global Osteoporosis Drugs Market Study Analysis: Emerging markets have a lot of potential for growth

The Global Osteoporosis Drugs Market was valued at $ Billion in 2019 and is anticipated to grow at a CAGR of 6.3% from 2020 to 2028. Osteoporosis is a medical condition where bones get weak and brittle due to lower bone mass that increases the risk of fracture in the hip, wrist, or spine. The lower mass density causes micro-architectural deterioration of bone tissues resulting in a higher risk of bone fracture. Osteoporosis makes bones so weak that they can break from falls and in severe cases from sneezing and minor bumps. Osteoporosis disease causes when new bone creation doesn’t keep up with old bone removal. Osteoporosis occurs due to several diseases and treatments that include anorexia, kidney disease, hyperthyroidism, surgical removal of ovaries, and alcoholism. Osteoporosis may also occur due to side effects of medications such as anti-seizure medication, proton pump inhibitors, chemotherapy, selective serotonin reuptake inhibitors, and glucocorticoid steroids which increase the rate of bone loss. Osteoporosis shows no symptoms until a bone fracture. According to International Osteoporosis Foundation, there are 1 in 3 women and 1 in 5 men suffering from osteoporotic fracture and worldwide and a bone breaks in every three seconds due to osteoporosis. The treatment of osteoporosis includes a healthy diet, weight-bearing exercises that empower weak bones, and medication such as antiresorptive drugs that restore bone density, anabolic drugs that maintain the osteoblast activity.

To request a free sample, Go To: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=006908

Global Osteoporosis Drugs Market Drivers And Restrain:
The major factors that have impacted the growth of the osteoporosis drugs market are the rapidly growing geriatric population resulting in an increased number of patients, and growing investments in R&D programs to get a cure for the disease, among others.

Rapid growing geriatric population:
The rise in the number of geriatric populations that are infected with osteoporosis disease is driving the osteoporosis drugs market. The threat of osteoporosis is coupled with age. According to International Osteoporosis Foundation, the number of individuals of 50+ age with osteoporosis in 2015 was 20 million in EU6, 3.8 million in France, 5.3 million in Germany, 4 million in Italy, 2.8 million in Spain, 500,000 in Sweden, and 3.5 million in UK. The changing lifestyle and unhealthy eating habits exert a negative influence on the bone health of an individual. The lifestyle habits like smoking, no exercise, and alcohol abuse increase the risk of osteoporosis in the aged population. The prevalence of osteoporosis in the geriatric population will propel the osteoporosis market growth during the forecast period.

Growing investments in R&D programs:
The rising demand for pharmaceuticals for osteoporosis treatment, owing to increased desire for improved osteoporosis care and increased awareness of drug availability, is attracting more and more expenditures into osteoporosis drug research and development. Major healthcare corporations are developing new products, and joint research programs are investing large sums of money to improve the treatment of osteoporosis. For drug development, patient organizations, government research organizations, and academic institutes are collaborating. The increasing spending in medication development by healthcare organizations and enterprises will propel the development of osteoporosis treatments.

The market is hampered by osteoporosis medicine side effects and a rigorous regulatory drug approval process.
Impact Of COVID-19 on the Osteoporosis Drugs Market:
• Impact on Market Size
• End-User Trend, Preferences, and Budget Impact
• Regulatory Framework/Government Policies
• Key Players Strategy to Tackle Negative Impact
• Opportunity Window

Global Osteoporosis Drugs Market Segments:
The global Osteoporosis Drugs market is further segmented into drug class, route of administration, and geography.

By Drug Class: Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Branded, Generics, and Others
By Route of Administration: Oral, Injectable, and Others

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Russia, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa and South America)
North America region is expected to witness lucrative growth in the osteoporosis drugs market. This is attributed to the presence of established healthcare infrastructure, high prevalence of osteoporosis patients, sustainable investment in healthcare operations, government initiatives, and increased investment in R&D activities. Asia Pacific region is also expected to dominate the osteoporosis drugs market. Increased government investments for research and development, consistent infrastructural improvements in healthcare facilities, a growing geriatric population with osteoporosis, and an unhealthy lifestyle are some of the factors that are expected to drive the osteoporosis drugs market growth in this region.

Key Players of Global Osteoporosis Drugs Market:
• Eli Lilly and Company
• Pfizer Inc.
• GlaxoSmithKline
• Novartis International
• Merck & Co. Inc
• Amgen Inc.
• Radius Health Inc
• F. Hoffmann-La Roche
• Teva Pharmaceutical Industries Ltd
• Novo Nordisk

For Any Query or Customization, Ask Our Industry Experts@https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=006908

Key Questioned Answered Through The Report:
• The Impact of COVID-19 on the global market
• What are the potential opportunities for new entrants in the global market
• What is the market Size and Forecast from 2020 to 2028?
• Key Players associated with the global Osteoporosis Drugs Market
• Value Chain Analysis of Global Osteoporosis Drugs Market
• What is the CAGR of the global Osteoporosis Drugs Market from 2021 to 2028
• Major Growth Factor, Challenges, Trends, and Opportunities in the global market
• Key outcomes of SWOT Analysis

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Contact: +1 773 644 5507 / +91 635 396 3987
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is market research, business intelligence, and advising service that offers creative solutions to a company's problems. Data beneficial to micro, small, medium, and large-scale businesses can be found in our market research studies. We offer a wide range of services, from data collection to business consulting.
Evolve Business Intelligence is built on account of technology advancement and our in-house AI-modelled data analysis and forecast tool – EvolveBI – provides extremely accurate data. This application tracks real-time statistics from Fortune's Global 2000 firms, including quarterly performance, annual performance, and recent changes.

This release was published on openPR.